Bloomage Biotech(SH:688363) Xin Lang Zheng Quan·2025-09-15 05:20Core Viewpoint - Huaxi Biological has shown a significant increase in stock price and market performance, despite a decline in revenue and net profit in the first half of 2025 [1][2]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms [1]. - The company has developed a full industry chain business system that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end users [1]. Financial Performance - As of July 31, 2025, Huaxi Biological reported a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% year-on-year [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed in the last three years [3]. Stock Performance - On September 15, Huaxi Biological's stock price increased by 2.01%, reaching 60.30 yuan per share, with a total market capitalization of 29.045 billion yuan [1]. - The stock has seen an 18.40% increase year-to-date, with a 0.50% rise over the last five trading days, a 12.00% increase over the last 20 days, and a 19.26% increase over the last 60 days [1]. Shareholder Information - As of July 31, 2025, the number of shareholders for Huaxi Biological was 32,500, an increase of 1.78% from the previous period, with an average of 14,799 circulating shares per shareholder, a decrease of 1.75% [2]. - Major shareholders include various ETFs, with notable changes in holdings among the top ten circulating shareholders [3].